Pell Bio-Med Technology (TWSE:6949) Is In A Good Position To Deliver On Growth Plans
Feb 05
Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedFeb 06, 2025
DataAggregated Company Financials
Companies65
- 7D1.1%
- 3M1.9%
- 1Y14.3%
- YTD7.7%
Over the last 7 days, the Biotech industry has remained flat, although notably PharmaEngine gained 18%. The past year has been better, since the industry has gained 13% in that time. As for the next few years, earnings are expected to grow by 70% per annum.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 07 Feb 2025 | NT$558.4b | NT$24.8b | -NT$10,902,841,000.00 | 38.3x | -51.2x | 22.5x |
| Sun, 05 Jan 2025 | NT$517.4b | NT$24.8b | -NT$10,902,841,000.00 | 35.4x | -47.5x | 20.9x |
| Tue, 03 Dec 2024 | NT$511.5b | NT$24.8b | -NT$10,782,551,000.00 | 37.8x | -47.4x | 20.7x |
| Thu, 31 Oct 2024 | NT$535.0b | NT$23.5b | -NT$10,829,095,000.00 | 40.9x | -49.4x | 22.8x |
| Sat, 28 Sep 2024 | NT$545.2b | NT$23.5b | -NT$10,829,095,000.00 | 35.2x | -50.3x | 23.2x |
| Mon, 26 Aug 2024 | NT$571.3b | NT$23.6b | -NT$10,755,142,000.00 | 34.4x | -53.1x | 24.3x |
| Wed, 24 Jul 2024 | NT$572.0b | NT$21.9b | -NT$11,110,100,000.00 | 42.4x | -51.5x | 26.1x |
| Fri, 21 Jun 2024 | NT$521.5b | NT$21.9b | -NT$11,110,643,000.00 | 42.2x | -46.9x | 23.8x |
| Sun, 19 May 2024 | NT$489.9b | NT$21.7b | -NT$11,004,689,000.00 | 43.2x | -44.5x | 22.5x |
| Tue, 16 Apr 2024 | NT$448.0b | NT$20.8b | -NT$12,061,940,000.00 | 49.2x | -37.1x | 21.5x |
| Thu, 14 Mar 2024 | NT$437.4b | NT$20.8b | -NT$9,912,839,000.00 | 42.9x | -44.1x | 21.1x |
| Sat, 10 Feb 2024 | NT$436.3b | NT$19.9b | -NT$9,857,794,000.00 | 40.5x | -44.3x | 21.9x |
| Mon, 08 Jan 2024 | NT$471.0b | NT$19.8b | -NT$9,748,146,000.00 | 39.3x | -48.3x | 23.8x |
| Wed, 06 Dec 2023 | NT$490.9b | NT$19.9b | -NT$9,737,975,000.00 | 43.1x | -50.4x | 24.7x |
| Fri, 03 Nov 2023 | NT$466.3b | NT$18.4b | -NT$10,823,013,000.00 | 49.9x | -43.1x | 25.3x |
| Sun, 01 Oct 2023 | NT$477.3b | NT$18.3b | -NT$10,774,226,000.00 | 43.3x | -44.3x | 26.1x |
| Tue, 29 Aug 2023 | NT$478.4b | NT$18.3b | -NT$10,598,878,000.00 | 41.6x | -45.1x | 26.1x |
| Thu, 27 Jul 2023 | NT$470.7b | NT$18.7b | -NT$10,724,655,000.00 | 44x | -43.9x | 25.2x |
| Sat, 24 Jun 2023 | NT$470.5b | NT$18.7b | -NT$10,709,428,000.00 | 42.6x | -43.9x | 25.2x |
| Mon, 22 May 2023 | NT$478.9b | NT$19.3b | -NT$9,957,876,000.00 | 42.5x | -48.1x | 24.9x |
| Wed, 19 Apr 2023 | NT$516.5b | NT$18.5b | -NT$9,609,324,000.00 | 42.7x | -53.8x | 27.9x |
| Fri, 17 Mar 2023 | NT$485.1b | NT$22.3b | -NT$7,407,579,000.00 | 36.6x | -65.5x | 21.8x |
| Sun, 12 Feb 2023 | NT$532.0b | NT$21.8b | -NT$7,832,470,000.00 | 38x | -67.9x | 24.4x |
| Tue, 10 Jan 2023 | NT$496.3b | NT$21.8b | -NT$7,778,690,000.00 | 36.2x | -63.8x | 22.8x |
| Thu, 08 Dec 2022 | NT$524.9b | NT$21.8b | -NT$7,522,211,000.00 | 38.6x | -69.8x | 24.1x |
| Sat, 05 Nov 2022 | NT$468.2b | NT$23.1b | -NT$6,633,590,000.00 | 37.4x | -70.6x | 20.3x |
| Mon, 03 Oct 2022 | NT$515.6b | NT$23.1b | -NT$6,633,590,000.00 | 37.4x | -77.7x | 22.3x |
| Wed, 31 Aug 2022 | NT$622.6b | NT$23.0b | -NT$6,443,294,000.00 | 41.9x | -96.6x | 27.1x |
| Fri, 29 Jul 2022 | NT$558.9b | NT$22.5b | -NT$5,642,821,000.00 | 31.5x | -99x | 24.8x |
| Sun, 26 Jun 2022 | NT$530.6b | NT$22.5b | -NT$5,642,821,000.00 | 32x | -94x | 23.5x |
| Tue, 24 May 2022 | NT$502.6b | NT$22.5b | -NT$5,642,821,000.00 | 31.7x | -89.1x | 22.3x |
| Thu, 21 Apr 2022 | NT$546.1b | NT$21.5b | -NT$5,726,696,000.00 | 34.8x | -95.4x | 25.5x |
| Sat, 19 Mar 2022 | NT$504.9b | NT$20.0b | -NT$4,463,544,000.00 | 26.7x | -113.1x | 25.2x |
| Mon, 14 Feb 2022 | NT$446.6b | NT$17.9b | -NT$5,532,702,000.00 | 26x | -80.7x | 25x |
Price to Earnings Ratio
-80.7x
Current Industry PE
- Investors are relatively neutral on the Taiwanese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 23.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 11% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | -1.42% | |
| Healthcare | 2.62% | |
| Biotech | 1.06% | |
| Biotech | 1.06% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6446 PharmaEssentia | NT$708.00 | 3.1% +NT$7.0b | 128.8% | PE127.7x | |
| 4162 PharmaEngine | NT$119.00 | 23.8% +NT$3.3b | 11.7% | PE46.2x | |
| 6550 Polaris Group | NT$46.75 | 4.2% +NT$1.4b | -33.0% | PS461.1x | |
| 4174 OBI Pharma | NT$62.00 | 8.4% +NT$1.3b | -7.9% | PS234.4x | |
| 4142 Adimmune | NT$24.90 | 11.9% +NT$1.1b | -17.3% | PS6.7x |